Safety of Biologics Approved for the Treatment of Rheumatoid Arthritis and Other Autoimmune Diseases: A Disproportionality Analysis from the FDA Adverse Event Reporting System (FAERS).

Ariane G S Araujo Helena Hiemisch Lobo Borba Fernanda Stumpf Tonin Luana Lenzi Rafael Venson Roberto Pontarolo Astrid Wiens

Published in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2019)

The results of this study highlight possible safety issues associated with biologics, whose relationship should be more thoroughly investigated. Our results contribute to future research on the identification of clinically relevant risks associated with these drugs, and may help contribute to their rational and safe use.

Keyphrases

single molecule
rheumatoid arthritis
adverse drug
disease activity
current status
human health
risk assessment
mass spectrometry
drug administration
replacement therapy
drug induced
electronic health record
high speed
data analysis